Senticell
Senticell is a biotechnology company developing a next-generation liquid biopsy platform that analyzes Red Cell-Bound Nucleic Acids (RBC-NAs) from red blood cells to detect diseases at their earliest stage. The platform leverages cfDNA and tDNA analysis to access immune-silent cellular signals, enabling early prediction and personalized treatment insights. The company is advancing diagnostics for lung, cervical, and pancreatic cancers, with FDA submissions planned for 2024–2025.
- Biotechnology
- Healthcare Technology
- Drug Discovery & Therapeutics
Funding
Founders
Founder details are not available yet.
Product
Problem
Traditional liquid biopsy approaches often rely on circulating tumor DNA that is rapidly degraded in the bloodstream, limiting sensitivity for early-stage cancer detection. Current diagnostic methods for conditions like lung, cervical, and pancreatic cancers frequently miss early molecular signals, delaying treatment and reducing patient outcomes.
Solution
Senticell has developed a diagnostic platform that analyzes nucleic acids bound to red blood cells (RBCs), which are the body's most abundant and immune-active cells. The technology harnesses cfDNA and tumor-derived DNA (tDNA) analysis to access cellular signals that are immune-silent yet rich in diagnostic information. By capturing these RBC-bound nucleic acids, the platform enables earlier disease prediction and personalized treatment insights across multiple cancer types. The company has completed preclinical proof-of-concept studies validating diagnostic accuracy and is advancing through CLIA pathways for early-access clinical deployment. Senticell also has a therapeutic platform that modulates immune activity and delivers RNA/drug payloads via modified RBCs for targeted action.
Target Audience
Primary customers are clinical diagnostic laboratories, oncologists, and healthcare providers seeking non-invasive cancer screening and monitoring tools, as well as pharmaceutical partners interested in companion diagnostics and targeted therapeutic delivery platforms.
Features
- Proprietary technology platform for analyzing Red Cell-Bound Nucleic Acids (RBC-NAs) as novel molecular biomarkers
- Dual cfDNA and tDNA analysis capability for accessing immune-silent cellular signals
- Diagnostics pipeline targeting lung, cervical, and pancreatic cancers with FDA submissions planned for 2024–2025
- Preclinical validation studies confirming diagnostic accuracy and therapeutic potential (2017–2020)
- Expansion roadmap into RNA payloads for therapeutic applications using modified RBCs for targeted drug delivery
- Pipeline growth planned into autoimmune, prenatal, and neurological disease diagnostics
- Next-gen, ultra-sensitive, same-day PCR solution that uses RBCs to amplify molecular signals in diseases